Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease thrombocytopenia
Comorbidity C0019158|hepatitis
Sentences 34
PubMedID- 20731135 This article represented a modern view on the problem of thrombocytopenia in patients with chronic hepatitis c, including it's role as an adverse event of antiviral therapy.
PubMedID- 25886818 Eltrombopag received accelerated fda approval in the united states for the treatment of patients with chronic idiopathic thrombocytopenic purpura (itp) in 2008 and full approval in 2011. eltrombopag has been shown to effectively increase platelet counts and reduce thrombocytopenia-associated complications in patients with itp and hepatitis c [14-16].
PubMedID- 20308017 Severe thrombocytopenia associated with acute autochthonous hepatitis e.
PubMedID- 20460556 Objective: to review the pharmacology and pharmacokinetics and evaluate the safety and efficacy of eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (itp) and thrombocytopenia associated with hepatitis c virus (hcv) cirrhosis.
PubMedID- 23857723 Laboratory investigation revealed severe acute hepatitis with thrombocytopenia and coagulopathy.
PubMedID- 24047408 thrombocytopenia in patients with hepatitis b virus-related chronic hepatitis: evaluation of the immature platelet fraction.
PubMedID- PMC4034027 Recent reports suggest that certain polymorphisms in type i ifn signaling molecules are associated with ifn-induced neutropenia and thrombocytopenia in patients with chronic hepatitis c. ifnγ binds to a cell-surface receptor composed of two transmembrane polypeptides ifgr1 and ifgr2 resulting in activation of the janus kinases jak1 and jak2, phosphorylation of stat1, formation of stat1 homodimers, and activation of a specific set of genes that encode the effector molecules responsible for mediating its biological activity.
PubMedID- 24653754 In november 2012, the us food and drug administration (fda) approved eltrombopag (promacta), an oral thrombopoietin agonist, for treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of ifn-based therapy.
PubMedID- 25728497 Background: there are many potential causes of thrombocytopenia in patients with chronic hepatitis c (chc).
PubMedID- 23440139 Thirteen pregnancies in ten patients diagnosed with autoimmune hepatitis, complicated by thrombocytopenia, were retrospectively analyzed.
PubMedID- 26364898 Recent studies have suggested a potential role of eltrombopag in the treatment of thrombocytopenia associated with hepatitis-c virus infection.
PubMedID- 24457056 We report the case of a 51 - year – old caucasian female who developed a severe, reversible, immune thrombocytopenia associated with hepatitis c virus infection.
PubMedID- 21188328 The goal of this study is to determine the prevalent mechanism of thrombocytopenia in patients with chronic hepatitis c and the clinical predictors of its severity.
PubMedID- 21120192 Suggested that thrombocytopenia in patients with hepatitis c infection may be due to a variety of non-immune and immune mechanisms [28].
PubMedID- 20796208 Prevalence of thrombocytopenia among patients with chronic hepatitis c: a systematic review.
PubMedID- 25764686 thrombocytopenia in patients with chronic hepatitis c represents an obstacle for the initiation of antiviral treatment.
PubMedID- 24621321 Here, we report a case of severe thrombocytopenia that developed in a patient with chronic hepatitis c treated with peg-ifn-α2a plus ribavirin in spite of having the itpa-cc genotype.
PubMedID- 19689996 thrombocytopenia in patients with chronic hepatitis c: a possible role of hcv on platelet progenitor cell maturation.
PubMedID- 25209590 However, clinical use of eltrombopag later confirmed that it is a safe and effective drug for immune thrombocytopenic purpura or thrombocytopenia associated with hepatitis c virus infection.
PubMedID- 23995112 Eltrombopag is effective for the treatment of chronic hepatitis with thrombocytopenia, and portal vein thrombosis at this time has rarely been reported.
PubMedID- 24304453 thrombocytopenia in patients with chronic hepatitis c may represent an obstacle for the initiation of antiviral treatment.
PubMedID- 24696622 Many recent studies have suggested a potential role for this novel agent in the treatment of thrombocytopenia associated with hepatitis-c infection.
PubMedID- 26417629 Eltrombopag (revolade ) and thrombocytopenia in patients with hepatitis c.
PubMedID- 20805953 The increase in platelet counts after pse may also improve the svr rate in chronic hepatitis c patients with thrombocytopenia [111213].
PubMedID- 23001404 Improvement of thrombocytopenia in hepatitis c-related advanced fibrosis patients after sustained virological response.
PubMedID- 20362495 The mortality rate was 6/95 (6.3%) in patients who developed plasma leakage, 3/42 (7.1%) in patients who developed hepatitis, 5/93 (5.4%) in patients with severe thrombocytopenia, and 3/12 (25%) in the patients who demonstrated together all these severe manifestations.
PubMedID- 20720351 A case of severe thrombocytopenia in a patient with chronic hepatitis c caused by a single administration of pegylated interferon alpha 2a subsequent to 48 weeks of pegylated interferon alpha 2b plus ribavirin therapy.
PubMedID- 20796207 Epidemiology of thrombocytopenia in patients with chronic hepatitis c: more than meets the eye.
PubMedID- 26278293 Association of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome with immune thrombocytopenia and graves' disease.
PubMedID- 25331767 Eltrombopag: a review of its use in the treatment of thrombocytopenia in patients with chronic hepatitis c.
PubMedID- 24714308 Another recent study concluded that anti-p antibodies contribute to thrombocytopenia associated with chronic hepatitis c virus infection [21].
PubMedID- 24128106 [eltrombopag for the treatment of thrombocytopenia in patients with chronic hepatitis c: two case reports].
PubMedID- 24731162 Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis c patients with thrombocytopenia and advanced fibrosis.
PubMedID- 22312391 However, thrombocytopenia also occurs in patients with chronic hepatitis c without cirrhosis.

Page: 1